Navigation Links
ALK Product Portfolio Not Affected by Glass Delamination Recall
Date:7/23/2013

ROUND ROCK, Texas, July 23, 2013 /PRNewswire/ -- A recent recall by a major manufacturer of Albumin Saline with Phenol (ABS) and Normal Saline with Phenol (NSP) products due to glass delamination has led to inaccurate claims of an "industry wide" recall of injectable pharmaceutical products in the allergy industry. ALK, a leading company focusing on allergy treatment, is pleased to announce that the entire ALK portfolio of products is not affected by this recall.

ABS and NSP are used as diluents with allergenic extracts to create customized immunotherapy treatments for patients. Various companies supply glass products to the pharmaceutical industry, but only one supplier has experienced glass delamination issues at this time. According to the Food and Drug Administration, glass delamination occurs when small volume vials shed thin, flexible glass fragments into the solution. http://1.usa.gov/15GEd1i  

"ALK does not use the glass products from the manufacturer that has experienced the problem of glass delamination," said Jorge Alderete, ALK Senior Vice President of Commercial Operations. "This recall is isolated to a single glass vendor, and is not what ALK would consider to be an 'Industry Wide' issue.  ALK takes this issue very seriously, and after thoroughly researching the issue through our scientific, quality, and regulatory departments, ALK is pleased to report our vials do not exhibit glass delamination and ALK has sufficient product available to meet patient needs."

About ALK
ALK is a research driven, global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. As the world leader in allergy immunotherapy, a treatment given to increase immunity to substances causing allergic symptoms, ALK is devoted to improving the quality of life for people with allergies by creating products that treat the cause of allergies. ALK and the Asthma and Allergy Foundation of America have partnered to create a unique online resource on allergy immunotherapy for patients:  www.fightthecauseofallergy.org ALK is also committed to supporting the business of allergy by providing diagnostic tools, automation software and customized business, technical and clinical consulting services.

Media Contact
Staci Young
ALK
512.990.6008
staci.young@alk.net


'/>"/>
SOURCE ALK
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. A*STARs SIMTech and NUS Faculty of Engineering Launch Joint Labs to Boost Manufacturing Productivity
2. Instrumentation Laboratory Awarded Premier Healthcare Alliance Contract For Hemostasis Product Line
3. Educating Key Stakeholder to Support a Successful Diabetes Product Launch
4. Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth
5. Global Decubitus Ulcer Treatment Products Industry
6. SAM Medical Products Selected a Winner in the 34th Annual Telly Awards
7. Abuse-Deterrent Formulations of Purdues OxyContin and Endo Pharmaceuticals Opana ER Have Not Increased PCPs Comfort When Prescribing These Products for Chronic Pain
8. Products From Eight Health-IT Vendors First to Receive Certification Under New Program Launched by IHE USA and ICSA Labs
9. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
10. Epilepsy Foundation Launches The "Epilepsy Innovation Seal Of Excellence" Recognizing Groundbreaking Product Candidates For People With Epilepsy
11. Ensil Canada Announces First Successful Test and Validation of Vastusys Line of Products in Ontario Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Februar 2017 LG Innotek hat heute die ... Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls der Konkurrenz. ... zwischen 200 und 280 nm und eignet sich damit für ... ihre DNA zerstört. Das Produkt von LG Innotek erzeugt ... ...
(Date:2/23/2017)... 23, 2017 Nevro Corp. (NYSE: NVRO), a global ... the treatment of chronic pain, today reported financial results for ... 2016 Accomplishment & Highlights: ... an increase of 228% as reported, over the prior year ... increase of 612% over the prior year ...
(Date:2/23/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs Price ... in the global Oesophageal Cancer market. The research answers ... key drugs marketed for Oesophageal Cancer and their clinical attributes? How ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... The narrative in “ Signal 8: An Australian Paramedic’s ... of his paramedic experiences. Schanssema describes the tragedies he saw, as well as his ... them. , Schanssema, initially unsure of the career path he wanted to take, found ...
(Date:2/24/2017)... ... ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently announced ... the Chairman of the Management Committee when IFN was originally formed in 2002 where ... investor/owners and development of the business plan. He became the first paid employee ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most award-winning sunscreen ... Fondo of Marin. For the second year in a row, cyclists will stay ... “We are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased ... KLS is a longtime supporter of the event. , "We are pleased that KLS ... Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track record of ...
(Date:2/23/2017)... California (PRWEB) , ... February 23, 2017 , ... ... Sports Development will host a diverse symposium on “Doping in Sport: ... Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be held ...
Breaking Medicine News(10 mins):